CC
MRVI icon

Clearline Capital’s Maravai LifeSciences MRVI Stock Holding History

Clearline Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-118,242
Closed -$285K – 126
2025
Q2 		$285K Sell
118,242
-87,097
-42% -$183K 0.01% 107
2025
Q1 		$454K Buy
205,339
+18,000
+10% +$71.1K 0.03% 108
2024
Q4 		$1.02M Sell
187,339
-1,900
-1% -$12.2K 0.14% 80
2024
Q3 		$1.57M Buy
+189,239
New +$1.64M 0.07% 106

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Clearline Capital's MRVI Position: Q3 2025 in Review

Clearline Capital sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 118,242 shares — an estimated $285K sold.

Clearline Capital first reported a position in MRVI in Q3 2024 and held it in 4 quarters. The position peaked at $1.57M in Q3 2024. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • Clearline Capital reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Clearline Capital sold 118,242 Maravai LifeSciences shares in Q3 2025, an estimated $285K.
  • Clearline Capital first reported a position in Maravai LifeSciences in Q3 2024 and held it in 4 quarters.
  • Clearline Capital's Maravai LifeSciences position peaked at $1.57M in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Clearline Capital's 13F filing for Q3 2025, filed 14 Nov 2025.